Given its late-stage trial success in boosting overall survival -- the gold standard of any cancer study -- it would seem that Celator Pharmaceuticals has indeed built something that could significantly improve the standard of care and, in turn, make this company one worth watching.
However, investors might want to keep some of their enthusiasm in check, at least until we get more insight into the efficacy of next-generation immunotherapies that are being developed for the indication.
Juno Therapeutics (NASDAQ:JUNO) is conducting a phase 1/2 study of its JTCR016 in AML, and results from that trial could be available in the first half of next year. Also, Kite Pharma (NASDAQ:KITE) has teamed up with Amgen (NASDAQ:AMGN) to discover next-generation immuno-therapies that could be used in AML, too.
Juno Therapeutics and Kite Pharma's efforts are admittedly in the earliest of stages of research. Thus, Celator Pharmaceuticals could have some running room that makes it appropriate for risk-tolerant investors. Nevertheless, investors will want to keep a close eye on Juno Therapeutics and Kite Pharma's progress, because their immuno-therapies could challenge Vyxeos in this indication someday.
SGYP website & Yahoo says 113m but I have seen the 150m only on 1 website, so who knows, that IS the amount that both sides are agreeing on & the source says the deal could be announced soon.... whoever thinks SGYP will be sold for a billion is a complete moron as the cost to get this far is around 1.5b + Paulson is not in this for a mere $2 upside & neither is the other 60 hedge funds !!!!! 3.6b is the offer because no one will bid more, this is AGN strategy to acquire SGYP quickly as they do not want a bidding war. Deal announcement may be next Mon ?
I've been seeing several articles about both companies in advanced talks with an announcement being imminent & if you dig a little deeper they have placed a value of 3.6 b this would imply that they are giving their best bid to close deal quickly & to shut out Shire. If that is the offer & a very good one then that makes the PPS around $31 a share based on 113 m shares. Would someone offer some technical info regarding debt ,warrants etc & how much per share investors would get, we have to keep in mind that AGN may throw in some stock with this deal although they wouldn't need to , thanks I'm a fundamental investor
Sentiment: Strong Buy
Pharmaceutical Sales Representative
Date posted: April 26 2016
In early 2015, Actavis completed the acquisition of Allergan. This combination united two growing, successful and profitable companies into a unique, global pharmaceutical company and a leader in a new industry model - Growth Pharma. In June 2015, the combined company changed its corporate name to Allergan plc and its stock ticker to NYSE:AGN.
Today, our nearly 30,000 talented global employees are creating an unrivaled foundation for long-term growth. We combine highly regarded brands and a best-in-class generics business with an enviable pipeline and lean, reliable operations to drive value for customers.
Join one of the world’s fastest growing specialty pharmaceutical companies!
At Allergan you will have the opportunity to thrive in a fast-paced, strategic environment where bold, innovative thinking isn’t just welcomed, it’s encouraged. Across all functions, we relish the opportunity to help our people fulfill their potential. Our rapid growth strategy means plenty of stretch assignments and opportunities to step into the spotlight.
As a pharmaceutical Sales Representative, you will have the opportunity to regularly call on health care professionals (primary care physicians, clinics, hospitals and pharmacies) within a specific geographic area. Day-to-day responsibilities consist of supporting the promotional efforts behind Allergan products, which includes organizing, tracking and distributing FDA regulated sample products to health care professionals. You will maintain a current and competent level of knowledge on the product line to be a reliable source of information to the health care professionals in the territory.
• Candidates should possess a minimum of 1 year of experience in outside business to business sales with a proven track record of success.
• Ability to work bot
Sentiment: Strong Buy
Since the matter is personal , lets just let it be, I doubt his departure will have any impact on SGYP being sold to AGN. Long SGYP
Roth Capital Reiterates “Buy” Rating for Synergy Pharmaceuticals Inc (SGYP)
Posted by Noah on Apr 21st, 2016 // No Comment
Synergy Pharmaceuticals logo Synergy Pharmaceuticals Inc (NASDAQ:SGYP)‘s stock had its “buy” rating reiterated by equities researchers at Roth Capital in a research report issued to clients and investors on Tuesday, AnalystRatings.NET reports.
SGYP has been the topic of a number of other reports. Citigroup Inc. lowered their target price on shares of Synergy Pharmaceuticals from $7.00 to $4.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 16th. Rodman & Renshaw restated a “buy” rating and issued a $20.00 price target on shares of Synergy Pharmaceuticals in a research report on Tuesday, January 26th. Zacks Investment Research restated a “buy” rating and issued a $4.25 price target on shares of Synergy Pharmaceuticals in a research report on Monday, February 8th. Finally, BTIG Research restated a “buy” rating and issued a $11.00 price target on shares of Synergy Pharmaceuticals in a research report on Monday, March 21st. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $11.97.
Synergy Pharmaceuticals (NASDAQ:SGYP) traded up 6.61% during trading on Tuesday, hitting $3.71. The company had a trading volume of 1,987,046 shares. Synergy Pharmaceuticals has a 12 month low of $2.50 and a 12 month high of $10.15. The company’s 50 day moving average price is $3.13 and its 200-day moving average price is $4.69. The company’s market cap is $421.80 million.
A number of institutional investors have recently made changes to their positions in SGYP. Allianz Asset Management AG increased its position in shares of Synergy Pharmaceuticals by 1.6% in the fourth quarter. Allianz Asset Management AG now owns 896,296 shares of the stock.
It works most of the time but sure wish I could use my 25 years of experience in the stock market to make better trades, I've only made 1.3m so guess I should buy a higher quality crystal ball next time & stop being such a loser!! A few of my other longs is PACB & CPXX & will most likely lose a lot of money on them.
We are on the same team, just trying to be realistic , I've got 6 figures invested so I'm all for a higher price,but seeing that article about company only worth 1b is a joke as that would imply $6-7 a share which is just ridiculous !!
When I first bought SGYP it was @ $3.90 & we know way way more more about this company, so why does the stock trade @ 3.60 ?? to your point we should be @ 10+ today but we are not, I hope your right that this will fly but only if we get multiple bids, I still say not more than $12 & lets hope that is all cash & not stock because I personally don't want to wait 3-4 months to tender my shares!! PS: How do we get above $12 with high debt,warrants, convertibles etc ??
Synergy Pharmaceuticals Inc (SGYP) Given Buy Rating at Rodman & Renshaw
Posted by paymon on Apr 22nd, 2016 // No Comments
Synergy Pharmaceuticals Inc logoRodman & Renshaw reiterated their buy rating on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) in a research report released on Thursday morning, MarketBeat reports. The brokerage currently has a $16.00 target price on the biopharmaceutical company’s stock.
Several large investors have recently bought and sold shares of SGYP. California State Teachers Retirement System raised its stake in Synergy Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 185,372 shares of the biopharmaceutical company’s stock valued at $1,051,000 after buying an additional 3,251 shares in the last quarter. Allianz Asset Management AG raised its stake in Synergy Pharmaceuticals by 1.6% in the fourth quarter. Allianz Asset Management AG now owns 896,296 shares of the biopharmaceutical company’s stock valued at $5,082,000 after buying an additional 14,429 shares in the last quarter. Ameriprise Financial Inc. raised its stake in Synergy Pharmaceuticals by 7.4% in the fourth quarter. Ameriprise Financial Inc. now owns 312,259 shares of the biopharmaceutical company’s stock valued at $1,770,000 after buying an additional 21,591 shares in the last quarter. Morgan Stanley raised its stake in Synergy Pharmaceuticals by 6.8% in the fourth quarter. Morgan Stanley now owns 423,520 shares of the biopharmaceutical company’s stock valued at $2,401,000 after buying an additional 27,037 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in Synergy Pharmaceuticals by 10.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 342,232 shares of the biopharmaceutical company’s stock valued at $1,941,000 after buying an additional 33,129 shares in the last quarter.
Synergy Pharmaceuticals (NASDAQ:SGYP) opened at 3.62 on Thursda
I have followed SGYP stock for over a year & it was a pipe dream that investors would get $18-25 in a BO, I'm 100% positive that SGYP will be sold sometime after Aug 2016 which is when the final results are due out for IBS-C, not sure why buyer would make bid before this. I do not see a BO price above $10 but with multiple bidders we may see upwards of $12 but not a dime more. Long SGYP
Allergan was also rumored late last week to be interested in acquiring Synergy Pharmaceuticals (SGYP). Synergy has filed has an NDA (New Drug Application) for its compound Plecanatide for the treatment of chronic idiopathic constipation which is expected to be approved soon. The product will likely be aimed at the same market as Linzess, a drug it has demonstrated some superior attributes to in trials. Ironwood Pharmaceuticals' (IRWD) Linzess currently does $450 million in annual sales and Ironwood believes it can be a $1 billion drug by 2020. With an enterprise value of just over $400 million, Synergy would be a potential bite-sized purchase for Allergan. Author Bret Jensen 04/18/16
Sentiment: Strong Buy
Allergan (AGN) Takeover of Synergy Pharmaceuticals (SGYP) May be Imminent - Source
April 15, 2016 3:13 PM EDT Send to a Friend
Allergan (NYSE: AGN) is in advanced talks to acquire Synergy Pharmaceuticals (Nasdaq: SGYP), according ...
Sentiment: Strong Buy
Teva's 40b bid for AGN's generic drug business is not final & may not pass US regulators , I see AGN stock falling $100 !! Hasn't everyone learned lessons from Valeant & Sunedison ??? companies today that has huge debt will not survive long term, its only a legal Ponzi scheme when companies are not responsible with investors money, & they wont be taking mine.
Sentiment: Strong Sell